Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperpolarized C-13 Pyruvate as a Biomarker of PI3K/mTOR Inhibition
NCT02913131Phase 2Terminated
- Sponsor
- Rahul Aggarwal
- Start
- Oct 2016
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of [1-13C]pyruvate in advanced malignant solid tumor and prostate cancer (PCa), sponsored by Rahul Aggarwal. Started Oct 2016; status: terminated.
02
Drugs
[1-13C]pyruvate
03
Conditions
advanced malignant solid tumorprostate cancer (PCa)
Beyond the preview
Go deeper on NCT02913131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02913131.